Feature | February 20, 2014

Medtronic Launches Miniaturized Cardiac Monitor

Medtronic Reveal Linq Insertable Cardiac Monitor Implantable Holter ECG Wireless
Medtronic Reveal Linq Insertable Cardiac Monitor Implantable Holter ECG Wireless

February 20, 2014 — Medtronic Inc. announced U.S. Food and Drug Administration (FDA) 510(k) clearance, CE marking and the global launch of its Reveal Linq Insertable Cardiac Monitor (ICM) System. Medtronic calls it the smallest implantable cardiac monitoring device available for patients. 

The Reveal Linq ICM is approximately one-third the size of a AAA battery (~1 cc), making it more than 80 percent smaller than other ICMs. The device is part of a system that allows physicians to continuously and wirelessly monitor a patient’s heart for up to three years, with 20 percent more data memory than its larger predecessor, Reveal XT. 

The system provides remote monitoring through the CarelinkNetwork in which physicians can request notifications to alert them if their patients have cardiac events. The Reveal Linq ICM is indicated for patients who experience symptoms such as dizziness, palpitation, syncope and chest pain that may suggest a cardiac arrhythmia, and for patients at increased risk for cardiac arrhythmias.

Placed just beneath the skin through a small incision of less than 1 cm in the upper left side of the chest, the Reveal Linq ICM is often nearly invisible to the naked eye once inserted. The device is placed using a minimally invasive insertion procedure, which simplifies the experience for both physicians and their patients. The Reveal Linq ICM is MR-Conditional, allowing patients to undergo magnetic resonance imaging (MRI) if needed.

The Reveal Linq system also includes the new MyCareLink Patient Monitor. That is a simplified remote monitoring system with global cellular technology that transmits patients’ cardiac device diagnostic data to their clinicians from nearly any location in the world.

For more information: www.reveallinq.com

Related Content

Infinix 4D CT

Toshiba's Infinix 4D CT, which combines CT with angiography in the interventional lab.

Feature | Angiography| September 28, 2016 | Tom Watson BS, RCVT, Clinical Analyst, MD Buyline
One of the more significant advancements for interventional X-ray (IXR) in the past few years has been a significantl
European Heart Rhythm Association, EHRA White Book 2016, EP Europace supplement, cardiac rhythm device use, Europe
News | EP Lab| September 27, 2016
In August, the European Heart Rhythm Association (EHRA) and EP Europace journal announced the release of the supplement...
BioTelemetry, CE Mark, Holter analysis software
News | Holter Monitoring Systems| September 27, 2016
BioTelemetry Inc. announced in late August that the company has received CE mark approval of its Holter analysis...
Sponsored Content | Videos | Inventory Management| September 21, 2016
With bundled payments putting increased pressure on hospitals to manage supply costs while providing quality patient
Medtronic, CRT, cardiac resynchroniazation therapy devices, heart failure, medication adherence, retrospective analysis, HFSA 2016
News | Heart Failure| September 20, 2016
Medtronic plc announced the results of an analysis that reveals patients increasingly adhere to heart failure...
don woodlock, GE Healthcare, EP CVIS, electrophyiology
Sponsored Content | Webinar | Cardiac PACS| September 16, 2016
Cardiac rhythm management (CRM) data is becoming increasingly important in the management of patients with implantabl
EBR Systems, FDA, WiSE Technology, Wireless Stimulation Endocardially, SOLVE-CRT study

The WiSE CRT System uses a tiny implant in the left ventricle to synchronize the heart, overcoming limitations of traditional cardiac resynchronization therapy (CRT) in heart failure patients. Graphic courtesy of Business Wire.

News | Cardiac Resynchronization Therapy Devices (CRT)| September 15, 2016
EBR Systems Inc. announced the U.S. Food and Drug Administration (FDA) has granted an Investigational Device Exemption...
Sponsored Content | Videos | Heart Failure| September 02, 2016
The Respicardia Remede System is a pacemaker-like implantable device designed to improve cardiovascular health by res
Respicardia, Remede, pacemaker for sleep apnea, central sleep apnea treatment

The Respicardia Remede System is a pacemaker-like implantable device designed to improve cardiovascular health by restoring natural breathing during sleep in patients with central sleep apnea.

News | Heart Failure| September 02, 2016
September 2, 2016 — Results from an international, randomized study show that an implanted nerve stimulator significa
Overlay Init